Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary inflammation inhibitors for hospitalized patients with COVID-19 pneumonia
RBR-5s2mqgPhase 3Recruiting
- Sponsor
- Faculdade de Ciências Médicas
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of icatibant and c1-esterase inhibitor in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (3 arms), sponsored by Faculdade de Ciências Médicas. Started Apr 2020; status: recruiting.
02
Drugs
icatibantc1-esterase inhibitor
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on RBR-5s2mqg.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-5s2mqg.